Screening for dihydropyrimidine dehydrogenase deficiency

被引：13

作者：

Grem, JL ^{[1
]}

机构：

[1] Univ Nebraska, Med Ctr, Sect Oncol Hematol, Omaha, NE 68198 USA

来源：

CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 14期

关键词：

D O I：

10.1158/1078-0432.CCR-05-0769

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：5067 / 5068

页数：2

共 9 条

[1] Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer:: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage [J].

Gamelin, E ;

Boissdron-Celle, M ;

Guérin-Meyer, V ;

Delva, R ;

Lortholary, A ;

Genevieve, F ;

Larra, F ;

Ifrah, N ;

Robert, J .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1105-1110

[2] Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors [J].

Grem, JL ;

Harold, N ;

Shapiro, J ;

Bi, DQ ;

Quinn, MG ;

Zentko, S ;

Keith, B ;

Hamilton, JM ;

Monahan, BP ;

Donavan, S ;

Grollman, F ;

Morrison, G ;

Takimoto, CH .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (23) :3952-3963

[3]

GREM JL, 2001, CANC CHEMOTHERAPY BI, P185

[4]

Keith B, 2002, CLIN CANCER RES, V8, P1045

[5] Toxicity of fluorouracil in patients with advanced colorectal cancer:: Effect of administration schedule and prognostic factors [J].

Lévy, E ;

Piedbois, P ;

Buyse, M ;

Pignon, JP ;

Rougier, P ;

Ryan, L ;

Hansen, R ;

Zee, B ;

Weinerman, B ;

Pater, J ;

Leichman, C ;

Macdonald, J ;

Benedetti, J ;

Lokich, J ;

Fryer, J ;

Brufman, G ;

Isacson, R ;

Laplanche, A ;

Quinaux, E ;

Thirion, P ;

Ryan, L ;

Hansen, R ;

Harrington, D ;

McFadden, E ;

Ribble, A ;

Jacobson, R ;

Zee, B ;

Weinerman, B ;

Pater, J ;

Leichman, C ;

Macdonald, J ;

Benedetti, J ;

Lokich, J ;

Fryer, J ;

Pignon, JP ;

Laplanche, A ;

Luboinski, M ;

Rougier, P ;

Brufman, G ;

Isacson, R ;

Vaitkevicius, V ;

Piedbois, P ;

Le Bourgeois, JP ;

Piedbois, Y ;

Gauthier, E ;

Lévy, E ;

Thirion, P ;

Durand-Zalenski, I ;

Buyse, M ;

Quinaux, E .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (11) :3537-3541

[6] Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test [J].

Mattison, LK ;

Ezzeldin, H ;

Carpenter, M ;

Modak, A ;

Johnson, MR ;

Diasio, RB .

CLINICAL CANCER RESEARCH, 2004, 10 (08) :2652-2658

[7] Dihydropyrimidine dehydrogenase activity in 150 healthy Japanese volunteers and identification of novel mutations [J].

Ogura, K ;

Ohnuma, T ;

Minamide, Y ;

Mizuno, A ;

Nishiyama, T ;

Nagashima, S ;

Kanamaru, M ;

Hiratsuka, A ;

Watabe, T ;

Uematsu, T .

CLINICAL CANCER RESEARCH, 2005, 11 (14) :5104-5111

[8] 5-FU THERAPEUTIC MONITORING WITH DOSE ADJUSTMENT LEADS TO AN IMPROVED THERAPEUTIC INDEX IN HEAD AND NECK-CANCER [J].

SANTINI, J ;

MILANO, G ;

THYSS, A ;

RENEE, N ;

VIENS, P ;

AYELA, P ;

SCHNEIDER, M ;

DEMARD, F .

BRITISH JOURNAL OF CANCER, 1989, 59 (02) :287-290

[9] Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil [J].

van Kuilenburg, ABP .

EUROPEAN JOURNAL OF CANCER, 2004, 40 (07) :939-950

← 1 →